UBS Group
DFTX

UBS Group’s Definium Therapeutics DFTX Stock Holding History

UBS Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.5M Buy
499,467
+5,490
+1% +$136K ﹤0.01% 2515
2026
Q1 		$9.34M Sell
493,977
-189,825
-28% -$3.22M ﹤0.01% 3436
2025
Q4 		$9.16M Buy
683,802
+131,993
+24% +$1.63M ﹤0.01% 3385
2025
Q3 		$6.51M Buy
551,809
+37,364
+7% +$348K ﹤0.01% 3768
2025
Q2 		$3.34M Buy
514,445
+406,419
+376% +$2.67M ﹤0.01% 4290
2025
Q1 		$632K Sell
108,026
-6,412
-6% -$45.9K ﹤0.01% 5676
2024
Q4 		$796K Sell
114,438
-13,860
-11% -$95.4K ﹤0.01% 5485
2024
Q3 		$730K Buy
128,298
+71,810
+127% +$499K ﹤0.01% 4924
2024
Q2 		$407K Buy
56,488
+32,104
+132% +$281K ﹤0.01% 5166
2024
Q1 		$229K Buy
24,384
+23,981
+5,951% +$137K ﹤0.01% 5761
2023
Q4 		$1.48K Sell
403
-4,111
-91% -$12.4K ﹤0.01% 8294
2023
Q3 		$14.1K Buy
4,514
+3,762
+500% +$15.5K ﹤0.01% 6966
2023
Q2 		$2.68K Sell
752
-9,050
-92% -$31.2K ﹤0.01% 7714
2023
Q1 		$31.1K Sell
9,802
-5,734
-37% -$19.1K ﹤0.01% 6774
2022
Q4 		$34.2K Sell
15,536
-6,711
-30% -$18.6K ﹤0.01% 7108
2022
Q3 		$78K Buy
22,247
+20,451
+1,139% +$196K ﹤0.01% 5932
2022
Q2 		$17K Buy
1,796
+374
+26% +$4.73K ﹤0.01% 7101
2022
Q1 		$24K Sell
1,422
-5,700
-80% -$98.9K ﹤0.01% 7245
2021
Q4 		$147K Buy
7,122
+7,052
+10,074% +$225K ﹤0.01% 5950
2021
Q3 		$2K Buy
70
+53
+312% +$2.29K ﹤0.01% 8966
2021
Q2 		$1K Buy
+17
New +$892 ﹤0.01% 9164

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

UBS Group's DFTX Position: Q2 2026 in Review

UBS Group increased its Definium Therapeutics (DFTX) stake by 1.1% in Q2 2026, buying an estimated $136K and bringing the position to 499,467 shares worth $23.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2515.

UBS Group first reported a position in DFTX in Q2 2021 and has held it in 21 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • UBS Group held 499,467 shares of Definium Therapeutics worth $23.5M as of Q2 2026.
  • UBS Group bought 5,490 Definium Therapeutics shares in Q2 2026, an estimated $136K.
  • Definium Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2515 holding.
  • UBS Group first reported a position in Definium Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.